DUBLIN--(BUSINESS WIRE)--The "IVD Assay Development Market Size, Share, Forecast, & Trends Analysis by Offering Technology, Application - Global Forecast to 2031" report has been added to ...
Register for our upcoming webinar “Accelerate your IVD assay development with the unique support of the Dynabeads team” and learn how Dynabeads technology and commercial partnership can help ...
REDDING, Calif., Oct. 24, 2024 /PRNewswire/ -- According to a new market research report, 'IVD Assay Development Market Size, Share, Forecast, & Trends Analysis by Offering (Assay Development, ...
QGEN partners with GENCURIX to develop oncology assays for the QIAcuityDx digital PCR platform. The pact launches QGEN's QIAcuityDx Partnering Program to broaden its clinical assay ecosystem. GENCURIX ...
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX) announced today that it has been awarded a $19 million contract from the Biomedical Advanced Research and Development Authority (BARDA ...
The Centers for Medicare and Medicaid Services’ (CMS) recent move to finalize a national coverage determination (NCD) for next generation sequencing (NGS) cancer panels underscores an emerging trend ...
IRVINE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a developer and manufacturer of diagnostic test systems and CDMO services provider, today announced it has entered into ...
Long-term partnership targets rapid assay development for local market needs “Runda Medical has maintained a close and positive working relationship with Ortho for nearly two decades. This partnership ...
Firm will seek approval of a range of diagnostic assays for the platform. Qiagen confirmed the receipt or FDA 510(k) clearance for both its Rotor-Gene Q MDx real-time PCR platform, and also the artus ...
Tempus AI gained FDA clearance for its RNA sequencing-based xR IVD device. TEM's xR IVD detects gene rearrangements in tumor tissues from solid malignancies. The device bolsters Tempus AI's role in ...
QIAGEN N.V. QGEN has announced a new partnership with South Korea-based GENCURIX, Inc. to develop oncology assays for use on the QIAcuityDx digital PCR (dPCR) platform. The molecular diagnostics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results